Advances in ultrasound elastography for nonalcoholic fatty liver disease

Magnetic resonance elastography plus Fibrosis‐4 versus FibroScan–aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH‐related fibrosis

“…Hepatic steatosis, lobular inflammation, and hepatocyte ballooning were combined to obtain the NAFLD activity score, ranging from 0 to 8. The median (interquartile range [IQR]) specimen length and number of portal tracts were 20 (16)(17)(18)(19)(20)(21)(22)(23)(24)(25) mm and 14 (11)(12)(13)(14)(15)(16)(17)(18)(19)(20), respectively, in the UCSD cohort and 17 (15)(16)(17)(18)(19)(20)(21)(22) mm and 12 (10)(11)(12)(13)(14)(15)(16)(17), respectively, in the Yokohama cohort.…”

“…[8,9,11] FibroScan is the first approved ultrasound-based modality, and LSM and CAP by FibroScan are associated with fibrosis stage and steatosis grade. [20] To further improve the diagnostic accuracy for liver fibrosis, one strategy is to combine noninvasive markers. The FAST score is a marker combining LSM by VCTE, CAP, and AST; and high diagnostic accuracy for NASH with significant activity and fibrosis was reported.…”